Navigation Links
Echinacea: Cold-Season Cure or Risk?

When sneezing and a prickly throat signal an oncoming cold, many people reach for what they believe will be a safe preventative – a tea or capsule containing //echinacea. In the first study to examine the effects of a botanical supplement on bacteria in the gastrointestinal tract, research at the University of Arkansas suggests people may be risking some unwelcome side effects with this common herbal remedy.

Although various botanical extracts have been shown in the laboratory to have some antimicrobial effects, previous to this research there had been no published information about their effect in vivo – in the human gastrointestinal tract. Research conducted by Jerald C. Foote, assistant professor of food and human nutrition, and graduate student Laura Hill yielded some surprising results and pointed to the need for further research.

The researchers worked with 15 healthy adults who took daily doses for 10 days of a supplement that offered a consistent amount of Echinacea purpurea, one of the commonly used varieties of Echinacea. The participants recorded any adverse effects, which proved to be minor. Stool specimens were collected and tested prior to using echinacea and again 10 days and 17 or 18 days following the supplementation.

Although the researchers had expected to see no result from the echinacea, they found that gastrointestinal bacterial counts increased for three groups of organisms during supplementation. Concentrations were increased for the total group of aerobic bacteria, and for the anaerobic Bacteroides in general and Bacteroides fragilis in particular. Anaerobic bacteria – those that grow where there is no oxygen – comprise the majority of the bacteria in the human colon. While Bacteroides are an important feature in the normal life of the colon, under certain conditions they also can act as pathogens, especially strains of B. fragilis.

Foote and Hill pointed out that increased Bacteroides concentr ations have been reported in people at high risk for colon cancer. Studies have shown that a specific strain of B. fragilis may contribute to inflammatory bowel disease and diarrhea.

The UA researchers noted that their study showed a significant increase in bacteria after only 10 days. They pointed out that the German Commission E, a body that sets guidelines for use of herbal products in Germany, suggests that echinacea can be used for up to eight weeks. In light of their research, Foote and Hill caution that “prolonged consumption could prove deleterious” to bacteria in the gastrointestinal tract, particularly for those who are ill.

Their research, they conclude, shows that larger studies are needed to target the specific bacteria affected and to determine whether particular components or the combination of components in echinacea affect bacteria in the human gastrointestinal tract.

Source-NewswiseSRM
'"/>




Related medicine news :

1. Do Computer Factories Enhance Cancer Risk?
2. Osteoporosis Meds and Jaw Pain: Whats the Risk?
3. Chinese Food- a Global Risk?
4. Botox at Your Own Risk?
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/21/2017)... ... July 21, 2017 , ... ... years, researchers from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that patients could ... after surgery, though activity levels decline over time. The study, presented today at ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... why concussion rates are on the rise, say researchers presenting their work at ... Toronto, Ontario, Canada. , “The combination of evaluating the patterns of change in ...
(Date:7/20/2017)... ... 2017 , ... ChenMed , a leading provider of value-based care for ... as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family ... of Ambulatory Services for the UVA Health System, brings 30 years of highly relevant ...
(Date:7/20/2017)... NY, July 20, 2017 (PRWEB) , ... ... ... Nastel Technologies, a global provider of enterprise-grade IT operations analytics and application ... arm of one of world’s largest healthcare services providers. , According to ...
(Date:7/20/2017)... ... July 20, 2017 , ... For individuals with extended ... The adjustable beds used in such facilities are specially designed to accommodate patients with ... support. , An inventor from Rochester, Ind., has invented the patent-pending PORTABLE ARM ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... a clinical-stage pharmaceutical company focused on the development of oral ... from the Israel Securities Authority to dual-list its common stock ... will commence trading on the TASE on July 12, 2017 ... of the Company, it is expected that Oramed will be ...
(Date:7/5/2017)... Wash. , July 5, 2017   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... cryopreservation freeze media ("BioLife"), today announced that it ... its debt holder and largest shareholder, to modify its ... Pursuant to the modification, WAVI agreed to exchange ...
(Date:6/30/2017)... In vitro diagnostics market firm Kalorama Information ... least ten diagnostic companies have successfully completed financings.  The ... a loan facility.  The size of these financings ranged ... Information provides a monthly IVD Market Trends Report ... "Diagnostics deals ...
Breaking Medicine Technology: